Navigation Links
Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
Date:7/9/2008

osis with a novel mechanism that may provide advantages over currently available therapies," said William R. Shanahan, M.D., Arena's Vice President and Chief Medical Officer. "We will review and evaluate the results with our consultants to develop the best approach to advance APD791 into Phase 2 clinical trials. We are also actively exploring partnership opportunities for this candidate."

"These positive results also demonstrate the utility of our focus on G protein-coupled receptor (GPCR) drug research and the general approach we take toward developing innovative treatments for serious medical conditions. Applying our GPCR focus and expertise, we've developed a pipeline of seven novel development stage drug candidates, five of which are in the clinic," stated Dominic P. Behan, Ph.D., Arena's Senior Vice President and Chief Scientific Officer.

About APD791

APD791 is a novel, oral and selective inverse agonist of the 5-HT2A serotonin receptor. Serotonin activation of the 5-HT2A receptor on platelets and vascular smooth muscle is thought to play an important role in events leading to thrombosis, and elevated serotonin levels have been associated with increased cardiovascular risk. Normally, when a platelet is activated by one of a number of factors, such as thrombin or collagen, the platelet releases serotonin, which, based on preclinical studies, promotes platelet aggregation, vasoconstriction and intimal hyperplasia. By blocking activation of the 5-HT2A receptor on platelets and other cardiovascular tissues, APD791 may curb these serotonin-mediated effects in the clinical setting, thereby reducing or preventing thrombosis. Furthermore, based upon preclinical studies, Arena believes that APD791, by preventing only the amplification of platelet aggregation induced by primary aggregators such as ADP and collagen, may allow sufficient platelet aggregation at therapeutic doses to avoid the bleeding risk associated with other anti-platelet agents whil
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
2. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
3. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
6. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
7. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
8. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
9. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
10. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
11. Isis Pharmaceuticals Conference Call Notice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... Introduction of new ... tools for radiosurgery/SBRT   The "Elements" ... enhancing the workflow for difficult to treat indications ... - comes full circle with the introduction of ... Elements enable on-the-fly generation of consistent treatment plans ...
(Date:4/24/2015)... , April 24, 2015 /CNW/ - T-Bird Pharma Inc. ... on developing premium quality medical marijuana products and a ... for Medical Purposes Regulations ( Canada ) ... certain of its shareholders, has closed the transaction announced ... Medna has acquired (the "Escrow Transfer") a total of ...
(Date:4/23/2015)... Lifesciences Corporation (NYSE: EW ), the global leader ... today reported net income for the quarter ended March 31, ... Net income for the same period a year earlier ... non-GAAP net income was $82.1 million, or $0.76 per ... ended March 31, 2015 increased 13.0 percent to $590.3 million ...
Breaking Medicine Technology:Brainlab Introduces New Generation of VMAT* for Brain and Spine at 3rd ESTRO in Barcelona 2T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences 2T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences 3Edwards Lifesciences Reports First Quarter Results 2Edwards Lifesciences Reports First Quarter Results 3Edwards Lifesciences Reports First Quarter Results 4Edwards Lifesciences Reports First Quarter Results 5Edwards Lifesciences Reports First Quarter Results 6Edwards Lifesciences Reports First Quarter Results 7Edwards Lifesciences Reports First Quarter Results 8Edwards Lifesciences Reports First Quarter Results 9Edwards Lifesciences Reports First Quarter Results 10Edwards Lifesciences Reports First Quarter Results 11Edwards Lifesciences Reports First Quarter Results 12Edwards Lifesciences Reports First Quarter Results 13Edwards Lifesciences Reports First Quarter Results 14Edwards Lifesciences Reports First Quarter Results 15Edwards Lifesciences Reports First Quarter Results 16
... 2011 Pennsylvania Association of Medical Suppliers (PAMS) ... Thompson (R-Centre) and Jason Altmire, (D-Allegheny) that would ... medical equipment.  H.R. 1041, titled the "Fairness in ... patient groups and consumer organizations, including the Three ...
... ViroPharma Incorporated (Nasdaq: VPHM ) today ... Use (CHMP) of the European Medicines Agency (EMA) has ... March 2011 recommending approval of a Centralized Marketing Authorization ... with hereditary angioedema (HAE) for routine prevention, pre-procedure prevention ...
Cached Medicine Technology:Bi-Partisan Legislation Introduced Would Repeal Controversial Medicare 'Competitive Bidding' Requirements for Home Medical Equipment 2Bi-Partisan Legislation Introduced Would Repeal Controversial Medicare 'Competitive Bidding' Requirements for Home Medical Equipment 3Bi-Partisan Legislation Introduced Would Repeal Controversial Medicare 'Competitive Bidding' Requirements for Home Medical Equipment 4ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union 2ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union 3ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union 4ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union 5ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union 6
(Date:4/24/2015)... Carvers' goal is to help an ... day in Breck. , Conveniently located in the ... from Breckenridge, this family-owned place since 1995, has ... rentals ( http://www.breckenridgeskishop.com/en/rent-equipment ) and more. , ... in May 2015. With style and function progressing ...
(Date:4/24/2015)... 24, 2015 On February 21st, 2015, ... an interview with ItsNotAboutMe.TV contributor Karen Salkin at Durkin ... treatment center for addiction, of which Wickstrom is the ... throughout the year, the EcoLuxe Lounge is a gathering ... and socially conscious products and services. Among the many ...
(Date:4/24/2015)... Anchor Health Administrators (Anchor), specialists in Long-Term Care ... exclusive agreement with LTC Solutions for All LLC (SFA) ... , Anchor has more than 18 years of experience ... and is currently the designated advocate for the American ... member benefit. , “I am very pleased to be ...
(Date:4/24/2015)... Joseph, Missouri (PRWEB) April 24, 2015 ... for veterinarians , UGA is now proud to be ... the care of 16,000 animals a year. This partnership ... care for their animals. , After providing an ... Missouri Veterinary Medical Teaching Hospital (VMTH) wanted to increase ...
(Date:4/24/2015)... “ Opera ” was featured on NewsWatch as part of ... technology products available to consumers. Andrew Tropeano, a technology expert ... with viewers how this is the fastest way to surf ... not be in existence. But each web browser is slightly ... different. Celebrating their 20th anniversary this year, Opera connects over ...
Breaking Medicine News(10 mins):Health News:Carvers Breckenridge Bike Rentals Offers Demo Mountain, Tandem, Bike Path Cruiser & JR. Bikes in May 2015 2Health News:Karen Salkin Talks with Per Wickstrom at the 2015 EcoLuxe Lounge and the "Salute to the Oscars" Celebration 2Health News:University of Missouri Veterinary Medical Teaching Hospital Teams with UGA 2Health News:A Web Browser That Connects over 350 Million People was Featured on NewsWatch Television 2
... irregularities are at greater risk of heart-rhythm abnormality: study ... who have severe sleep-related breathing problems are at increased ... , The study included 2,911 men who underwent sleep ... episodes of paused or shallow breathing during sleep were ...
... (NYSE: HGR ) announced today that it plans to ... the second quarter ending June 30, 2009, on Tuesday, July 28, ... The conference call is scheduled to begin at 9:00 a.m., EDT, ... 1-800-931-9710. In addition, a replay will be available until August 5, ...
... U.S. patent infringement lawsuit was filed on June 10, ... America, Inc. The lawsuit, brought by Aperio Technologies, ... of Delaware, accuses products incorporating Hamamatsu Photonics K.K. NanoZoomer(R) ... and 7,518,652. , , The lawsuit follows a ...
... YORK, June 23 FamilyCord , one of ... their title sponsorship of the WBLI 106.1 Baby Shower event where ... for a day of fun, prizes, and education on June 28. ... storing cord blood to protect newborns against 70 life-threatening diseases. Leading ...
... June 23 The National Medical Association (NMA) congratulates President ... their work with PhRMA to bring down health care costs ... the adoption of Medicare Part D has been a tremendous ... the system," said Dr. Mohammad N. Akhter, Executive Director of ...
, Journalists and other readers should disregard the news release, PHT Names VP to Lead Sales of A-Claim Payment Solution for Doctors, Hospitals, issued 23-Jun-2009. The release was transmitted prema...
Cached Medicine News:Health News:Sleep Disorders Linked to Arrhythmias 2Health News:U.S. Patent Infringement Lawsuit Filed by Aperio Technologies, Inc. 2
Suspend® Tutoplast® Processed Fascia Lata is your naturally safe and strong choice for pelvic floor reconstruction. Suspend comes from a dense matrix of collagen bundles and transverse fasc...
... Bard® Dermal Allograft ... of most pelvic floor ... highly resistant to suture ... and serves as a ...
... Viral RNA Mini Kit allows ... from cell-free fluid samples. Examples ... can be isolated with this ... limited to, RNA from hepatitis ...
The PersonalLAB junior is an automated microplate analyzer capable of fully automating immunoenzymatic techniques using a microplate format, per the reagent manufacturer's instruction for use and spe...
Medicine Products: